Nav: Home

Different breast cancer treatment options vary widely in their cost-effectiveness

April 10, 2017

A new study published today in the Journal of the National Cancer Institute indicates that different therapies for early-stage breast cancer have very different relative values. Some therapies may have fewer complications and be much less expensive than others. Women may be making treatment decisions based on factors other than medical value.

Recommended options for early breast cancer include lumpectomy plus whole breast irradiation therapy, lumpectomy plus brachytherapy, mastectomy alone, mastectomy plus reconstruction, and, in older women, lumpectomy alone. Researchers performed a comparative examination of each treatment's complications and cost to assess their relative values.

Researchers identified 105,211 women with early breast cancer diagnosed between 2000 and 2011 and identified treatment complications within 24 months of diagnosis and compared complications by treatment. Mean total and complication-related cost were calculated from a payer's perspective.

Lumpectomy plus whole breast irradiation treatment was the most commonly used treatment. Mastectomy plus reconstruction was associated with nearly twice the complication risk of lumpectomy plus whole breast irradiation treatment (54.3% vs. 29.6% complication risk among for younger women with private insurance and 66.1% vs. 37.6% complication risk among older women with Medicare) and was also associated with higher adjusted total cost (an average $22,481 more for younger women; an average $1,748 greater for older women with Medicare) and complication-related cost (an average $9,017 greater for the younger cohort; $2092 greater for the Medicare cohort). Brachytherapy had modestly higher total cost and complications than whole breast irradiation treatment. Lumpectomy alone entailed lower cost and complications in the Medicare cohort only.

In recent years, there has been an increase in the use of bilateral mastectomy and reconstruction to treat early breast cancer. While some of these procedures are medically necessary, the choice for mastectomy is often driven by nonmedical factors such as patient preferences for more "complete" cancer treatment by removing the entirety of the affected organ, patient fears of in-breast recurrence following a lumpectomy plus whole breast irradiation, or patient anxiety regarding the need for ongoing mammographic surveillance of the conserved breast.

The finding of that mastectomy plus reconstruction treatment resulted in a very high cost (compared with lumpectomy plus whole breast irradiation treatment) highlights an important conflict in an era focused on "value" in health care. Patients may prefer a more expensive treatment such as mastectomy plus reconstruction treatment for nonmedical reasons when a less expensive treatment such as lumpectomy plus whole breast irradiation treatment may be equally effective from a purely medical perspective.

"We believe that this research is helpful to frame the conversation between a woman and her physicians regarding the trade-offs between lumpectomy with whole breast irradiation and mastectomy with reconstruction" said the paper's lead author, Benjamin Smith, associate professor in the department of radiation oncology at the University of Texas MD Anderson Cancer Center. "While mastectomy with reconstruction is sometimes the best treatment for an individual patient, it is important for patients to understand the potential for complications, some of which can be quite significant."
-end-
The paper "Cost and Complications of Local Therapies for Early-Stage Breast Cancer" is available at:http://jnci.oxfordjournals.org/content/109/1/djw178

Direct correspondence to:

Benjamin D. Smith
Department of Radiation Oncology, Unit 1202
University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, TX 77030
bsmith3@mdanderson.org

To request a copy of the study, please contact: Daniel Luzer- daniel.luzer@oup.com

The Journal of the National Cancer Institute publishes peer-reviewed original research from around the world and is internationally acclaimed as the source for the most up-to-date news and information from the rapidly changing fields of cancer research and treatment. For the past several years, the JNCI has been ranked as one of the most-cited original-research cancer journals by the Institute of Scientific Information in its annual Journal Citation Reports.

Sharing on social media? Find Oxford Journals online at @OxfordJournals

Oxford University Press USA

Related Cancer Treatment Articles:

NUS researchers show potential liver cancer treatment by targeting cancer stem-like cells
NUS researchers from the Cancer Science Institute of Singapore and the N.1 Institute for Health have shown the potential use of small molecule inhibitors to treat advanced liver cancer.
Breast cancer gene a potential target for childhood liver cancer treatment
Hepatoblastoma is a rare liver cancer that mainly affects infants and young children and is associated with mutations in the β-catenin gene.
Light therapy could replace opioids as main treatment for cancer treatment side effect
A worldwide coalition of researchers and clinicians has agreed that light therapy is among the most effective interventions for the prevention of oral mucositis, painful ulcers in the mouth resulting from cancer therapy.
Scanning for cancer treatment
11,000 people are predicted to die from acute myeloid leukemia (AML) in 2019.
Visualizing better cancer treatment
Researchers have engineered nanoscale protein micelles capable of both delivering chemotherapeutic drugs and of being tracked by MRI.
More Cancer Treatment News and Cancer Treatment Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...